Pricing

Anavex Life Sciences Corp (AVXL)

followers ยท 1 like
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: Christopher U. Missling
Employees: 40
Web site: anavex.com
630 5TH AVENUE, 20TH FLOOR, NEW YORK, NY, 10111
844-689-3939
    Formally known as:
  • Anvx Lf Scn Corp
Stock Split History
Date Ratio
2006-06-13 6:1
2015-10-07 1:4
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available